NASDAQ:NRIX

Nurix Therapeutics Stock News

Healthcare > Biotechnology

Buy NRIX

*Your capital is at risk

$15.48

-0.89 (-5.44%)

At Close: Jun 03, 2026

Nurix Therapeutics Reports Third Quarter Fiscal 2021 Financial Results and Provides a Corporate Update

04:02pm, Thursday, 14'th Oct 2021

Initiated Phase 1 trial of lead CBL-B E3 ligase inhibitor program NX-1607 in patients with cancer

Nurix Therapeutics Expands its Board of Directors with the Addition of Two Industry Leaders

07:00am, Thursday, 30'th Sep 2021

SAN FRANCISCO, Sept. 30, 2021 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced the appointments of

Nurix Therapeutics Announces Appointment of Stefani A. Wolff as Chief Operating Officer and Executive Vice President, Product Development

04:01pm, Monday, 21'st Jun 2021

SAN FRANCISCO, June 21, 2021 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced that Stefani A. Wolf

Nurix Therapeutics Appoints Industry Leader Clay Siegall, Ph.D., to its Board of Directors

04:00pm, Tuesday, 01'st Jun 2021

SAN FRANCISCO, June 01, 2021 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced the appointment of C

Nurix Therapeutics Announces Upcoming Presentation of NX-5948 Preclinical Data at the EULAR 2021 Virtual Congress

07:00am, Friday, 21'st May 2021

NX-5948, a potent selective degrader of BTK, significantly reduces inflammation in a model of autoimmune disease NX-5948, a potent selective degrader of BTK, significantly reduces inflammation in a mo

Nurix Therapeutics Reports First Quarter Fiscal 2021 Financial Results and Provides a Corporate Update

04:01pm, Tuesday, 13'th Apr 2021

On track to initiate Phase 1 trials for four wholly owned drug candidates in 2021

Nurix Therapeutics Announces Participation in the 20th Annual Needham Virtual Healthcare Conference

07:00am, Wednesday, 07'th Apr 2021

SAN FRANCISCO, April 07, 2021 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced that Arthur T. S

Nurix Therapeutics Announces Collaboration for the Discovery of Novel Drugs to Treat Pediatric Cancers

09:31am, Tuesday, 16'th Mar 2021

Research focused on targeted degradation of MYCN for the potential treatment of neuroblastoma and medulloblastoma Program is one of four in Alex's Lemonade Stand Foundation-funded $18.5 million Crazy

Nurix Therapeutics Announces Presentation of NX-1607 Preclinical Data at AACR

05:12pm, Wednesday, 10'th Mar 2021

CBL-B inhibitor NX-1607 mediates anti-tumor activity through both T cells and NK cells Preclinical tumor models support clinical development of NX-1607 as monotherapy or in combination with PD-1 block

Nurix Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares

04:01pm, Tuesday, 09'th Mar 2021

SAN FRANCISCO, March 09, 2021 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced the closing of its

Top Fintech Company

featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by